INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
批准号:
7187263
负责人:
RICHARD H. EBRIGHT
金额:
$59.85万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2011-12-31
关键词:
AddressAffectAnti-Bacterial AgentsBacterial InfectionsBindingBiological FactorsBiological WarfareBioterrorismClinicalCloningComplexCrystallographyDNADNA-Directed RNA PolymeraseDevelopmentElementsEscherichia coliEvaluationExhibitsFutureGene ClusterGenetic TranscriptionGrowthLactonesMediatingMolecular CloningMolecular ConformationPolymerasePublic HealthPyronesRNA Polymerase IRNA Polymerase IIRNA Polymerase IIIReactionResearch PersonnelResistanceRifabutinRifampinRifamycinsScreening procedureStructureThermus thermophilusTranscription InitiationWorkbaseinhibitor/antagonistnovelprogramsrifamycin SVrifapentinesingle moleculesingle-molecule FRETsmall moleculetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Preliminary work establishes that three natural products-the polyketide-derived a-pyrone myxopyronin, the Dolyketide-derived a-pyrone corallopyronin, and the polyketide-derived macrocylic lactone ripostatin-inhibit bacterial RNA polymerase (RNAP) through interactions with the RNAP "switch region," a structural element that mediates conformational changes required for RNAP to bind and retain the DNA template in transcription. The compounds do not inhibit eukaryotic RNAP I, RNAP II, or RNAP III. The compounds potently inhibit Gram-positive and Gram-negative bacterial growth, exhibit no cross-resistance with the inhibitors of bacterial RNAP in current clinical use in therapy of bacterial infection (the rifamycin antibacterial agents, rifampicin, rifapentine, and rifabutin), and exhibit no cross-resistance with other inhibitors of bacterial RNAP under evaluation for future clinical use in therapy of bacterial infection. The proposed work will use x-ray crystallography, ensemble and single-molecule fluorescence resonance energy transfer, single-molecule nanomanipulation, molecular cloning, surrogate-host expression, structure-based screening, and de novo screening, to address four specific aims:
Specific Aim 1: Determination of structures of complexes of RNAP with switch-region-target inhibitors Specific Aim 2: Determination of mechanisms of inhibition of RNAP by switch-region-target inhibitors Specific Aim 3: Cloning, characterization, and surrogate-host expression of biosynthetic gene clusters for switch-region-target inhibitors
Specific Aim 4: Identification and characterization of novel switch-region-target inhibitors.
The results will enable development of new broad-spectrum antibacterial agents that will be effective against bacterial strains resistant to currently used antibacterial agents. As such, the results will have direct relevance to public health and to development of countermeasures against bacterial strains that could be used in biowarfare or bioterrorism. In addition, the results will contribute to understanding RNAP structure and function and will provide tools for analysis of RNAP structure and function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bacterial Transcription Complexes
-
批准号:10388566
-
项目类别:
-
资助金额:$5.1万
-
财政年份:2021
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10394990
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10613893
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8978290
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8603843
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8782465
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8474439
-
项目类别:
-
资助金额:$104.89万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8476980
-
项目类别:
-
资助金额:$114.02万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8288777
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8105468
-
项目类别:
-
资助金额:$120.94万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8697004
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:7989018
-
项目类别:
-
资助金额:$124.8万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
BACTERIAL TRANSCRIPTION COMPLEXES
-
批准号:7932650
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2009
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7337094
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7742240
-
项目类别:
-
资助金额:$58.22万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7540990
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:8009521
-
项目类别:
-
资助金额:$55.96万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6363271
-
项目类别:
-
资助金额:$16.32万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6046298
-
项目类别:
-
资助金额:$15.85万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:2668516
-
项目类别:
-
资助金额:$14.93万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
海外基金